

Inovio Pharmaceuticals added to the prestigious NASDAQ Biotechnology Index

Dr. J. Joseph Kim, President and CEO proclaimed “another milestone achieved” as Inovio Pharmaceuticals {NASDAQ: INO} celebrated being added to the influential and prestigious NASDAQ Biotechnology Index, effective December 22nd 2014.

Comment

Dr. J. Joseph Kim, President & CEO of Inovio, said, “This addition is another milestone for Inovio as we advance our DNA immunotherapies and vaccines. We’re pleased to meet the criteria for inclusion into the most influential biotechnology index.”

Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index

PLYMOUTH MEETING, Pa. – December 15, 2014 – Inovio Pharmaceuticals, {NASDAQ: INO} announced today it has been added to the NASDAQ Biotechnology Index (NBI).

The addition to the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually in December. The NASDAQ Biotechnology Index forms the basis for the iShares

NASDAQ Biotechnology Index Fund (IBB) which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges.

For more information about the NASDAQ Biotechnology Index visit;

<https://indexes.nasdaqomx.com/Index/Overview/NBI>

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and infectious diseases. Their immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favourable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com

CONTACTS

Investors: Bernie Hertel, Inovio Pharmaceuticals,
858-410-3101, bhertel@inovio.com

Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211,
jrichardson@inovio.com